Treventis Awarded $2.97M Grant from the U.S. Department of Defense
Funds for Development of Its Anti-Tau Drug Against Neurodegenerative Diseases October 18, 2022 BERNVILLE, Pennsylvania – Treventis Corporation, a privately held biotechnology […]
Archives: News
Treventis founder Sultan Darvesh awarded Jubilee Medal
Treventis is pleased to congratulate our founder Dr. Sultan Darvesh, neurologist and Dalhousie professor, for being one of the first 70 Nova […]
Treventis founders give invited lectures at WATOC
Treventis founders Donald Weaver and Christopher Barden are both invited speakers at the 12th Triennial Congress of the World Association of Theoretical […]
Dr. Donald Weaver, Oskar Fischer Prize Winner
Congratulations to our own Dr. Donald Weaver, Treventis founder and Chief Medical Officer, for being an Oskar Fischer Prize winner! Don will […]
Treventis Attending BIO 2022
Treventis will be at BIO next week -in person! Please ping us if you would like to meet in person or virtually. […]
Treventis attends RESI Nov 2021
Treventis CEO Christopher Barden attended the second of the fall Redefining Early Stage Investments (RESI) conferences (held virtually this year due to […]
Treventis CSO Mark Reed gives invited lecture at Undruggable Leaders Forum
From September 15-16, 2021, the “Undruggable Leaders Forum” was a virtual meeting focused on new approaches to historically intractable targets. Treventis was […]
Treventis attends RESI Partnering Week 2021
For the first time in several years, Treventis CEO Christopher Barden attended the Redefining Early Stage Investments (RESI) conference (held virtually this […]
Treventis attends Virtual AAIC 2021
Treventis was well represented at the Alzheimer Association International Conference, running from Jul 26-30, 2021 (held virtually and in Denver, CO). CEO […]
Treventis attends BIO Digital Conference
Treventis was represented at the BIO Digital International Convention (for a second year in a row, held virtually due to COVID-19) with […]